Washington University’s Moderna MRNA Stock Holding History

Washington University’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150,000	Closed	-$4.42M	–	3
2025 Q4	$4.42M	Hold	150,000	–	–	2.24%	3
2025 Q3	$3.87M	Hold	150,000	–	–	2.17%	3
2025 Q2	$4.25M	Hold	150,000	–	–	3.5%	3
2025 Q1	$4.25M	Hold	150,000	–	–	3.84%	2
2024 Q4	$6.24M	Hold	150,000	–	–	5.31%	2
2024 Q3	$10M	Hold	150,000	–	–	6.5%	2
2024 Q2	$17.8M	Hold	150,000	–	–	8.11%	2
2024 Q1	$16M	Hold	150,000	–	–	5.91%	4
2023 Q4	$14.9M	Hold	150,000	–	–	7.36%	4
2023 Q3	$15.5M	Hold	150,000	–	–	5.57%	4
2023 Q2	$18.2M	Hold	150,000	–	–	6.83%	4
2023 Q1	$23M	Hold	150,000	–	–	6.07%	5
2022 Q4	$26.9M	Hold	150,000	–	–	7.91%	4
2022 Q3	$17.7M	Hold	150,000	–	–	6%	4
2022 Q2	$21.4M	Hold	150,000	–	–	7.94%	4
2022 Q1	$25.8M	Hold	150,000	–	–	9.31%	4
2021 Q4	$38.1M	Hold	150,000	–	–	10.67%	3
2021 Q3	$57.7M	Sell	150,000 -50,000	-25%	-$18.4M	16.76%	3
2021 Q2	$47M	Buy	+200,000	New	+$35.7M	16.76%	3

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Washington University's MRNA Position: Q1 2026 in Review

Washington University sold out of Moderna (MRNA) in Q1 2026, closing a stake of 150,000 shares — an estimated $4.42M sold.

Washington University first reported a position in MRNA in Q2 2021 and held it in 19 quarters. The position peaked at $57.7M in Q3 2021. 725 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Washington University reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Washington University sold 150,000 Moderna shares in Q1 2026, an estimated $4.42M.
Washington University first reported a position in Moderna in Q2 2021 and held it in 19 quarters.
Washington University's Moderna position peaked at $57.7M in Q3 2021.
725 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Washington University's 13F filing for Q1 2026, filed 6 May 2026.